Transarterial Chemoembolization Market Size, Share, Growth Analysis, By Product(Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By End-User(Strawberry, apple, mango, mixed fruit blends), By Technology(Lipiodol-based TACE, Drug-Eluting Bead TACE Technology), By Region - Industry Forecast 2025-2032

Transarterial Chemoembolization Market size was valued at USD 17.81 Billion in 2023 and is poised to grow from USD 18.79 Billion in 2024 to USD 28.83 Billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The global transarterial chemoembolization market has witnessed changes in consumers’ preferences and demands recently due to its minimally invasive treatment of hepatoma.

Demand for TACE continues increasing worldwide since the prevalence of liver cancer globally is increasing. The increase in liver cancer is mainly caused by risk factors e.g., hepatitis infections, alcohol consumption, and non-alcoholic fatty liver disease among others.

With the rapid innovations in medical technology, more elaborated and precise types of transarterial chemoembolization (TACE) are on the market nowadays. Adapted imaging procedures, emboli, and drug transportation devices have made TACE more accurate and cost-efficient, fueling industry growth.

Increased awareness of symptoms of liver cancer and how important it is for early diagnosis has led more patients to seek health care services in the initial stages. This is why TACE may be prescribed to patients with intermediate-grade liver cancer and thus support industry growth.

However, the market landscape could differ between regions due to issues like health care infrastructure, incidence rate of risk factors as well as regulatory set-ups. Particularly, Asia-Pacific have had huge developments, particularly because of higher liver cancer levels in some countries such as China.